Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 22, 2021 08:00 ET | Source: Century Therapeutics, Inc.

Century Therapeutics to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference

PHILADELPHIA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...
November 10, 2021 07:30 ET | Source: Century Therapeutics, Inc.

Century Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates

Lead program, CNTY-101 in relapsed/refractory non-Hodgkin’s lymphoma, remains on track for IND filing in mid-2022 Pre-clinical data from CNTY-101 program and CAR-iT platform to be presented at the...
November 04, 2021 09:00 ET | Source: Century Therapeutics, Inc.

Century Therapeutics to Present at the 63rd American Society of Hematology Annual Meeting and Host Virtual Research & Development Update

PHILADELPHIA, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...
October 07, 2021 07:30 ET | Source: Century Therapeutics, Inc.

Century Therapeutics and Outpace Bio Enter Research Collaboration in CAR Engineering

Collaboration enables Century to explore Outpace’s protein solutions for cell therapy to enhance functionality of iPSC platform Initial program to focus on hematological malignancies with option to...
September 17, 2021 16:01 ET | Source: Century Therapeutics, Inc.

Century Therapeutics Announces Its Addition to the Russell 2000® Index

PHILADELPHIA, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...
August 12, 2021 08:00 ET | Source: Century Therapeutics, Inc.

Century Therapeutics Reports Second Quarter 2021 Financial Results and Business Updates

Continued Company investment across our iPSC platforms, programs, and manufacturingLead program, CNTY-101, remains on track for IND filing in mid-2022Recent IPO with net proceeds of approximately...
June 22, 2021 16:01 ET | Source: Century Therapeutics, Inc.

Century Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

PHILADELPHIA, June 22, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...
June 17, 2021 18:15 ET | Source: Century Therapeutics, Inc.

Century Therapeutics Announces Pricing of Initial Public Offering

PHILADELPHIA, June 17, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics, an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology,...